Skip to main content

01-04-2019 | Non-small cell lung cancer | Video | Article

Expert commentary: TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC

Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

Related topics

More on this topic

Image Credits